BVF Inc. IL Decreases Holdings in XOMA Royalty Corporation $XOMA

Key Points

• BVF Inc. IL has reduced its stake in XOMA Royalty Corporation by 17.9%, selling 650,717 shares and now holding approximately 2.4% of its investment portfolio in the biotech firm, valued at $59.45 million.
• GAMMA Investing LLC increased its stake in XOMA Royalty by 1,063.8%, while other firms like Deutsche Bank AG reported significant increases in their holdings, indicating heightened institutional interest.
• XOMA Royalty's stock rose by 7.1%, with the company recently announcing a quarterly EPS of $0.48, surpassing analysts' expectations and leading to a consensus rating of "Moderate Buy" among financial analysts.

BVF Inc. IL lowered its position in XOMA Royalty Corporation (NASDAQ:XOMA - Free Report) by 17.9% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,983,026 shares of the biotechnology company's stock after selling 650,717 shares during the period. XOMA Royalty accounts for 2.4% of BVF Inc. IL's portfolio, making the stock its 8th largest holding. BVF Inc. IL owned about 24.96% of XOMA Royalty worth $59,452,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of XOMA. Stonepine Capital Management LLC raised its position in XOMA Royalty by 3.3% in the 1st quarter. Stonepine Capital Management LLC now owns 129,813 shares of the biotechnology company's stock worth $2,587,000 after purchasing an additional 4,113 shares during the last quarter. Nuveen LLC bought a new position in XOMA Royalty in the 1st quarter worth approximately $286,000. Deutsche Bank AG raised its position in XOMA Royalty by 5,087.9% in the 1st quarter. Deutsche Bank AG now owns 6,433 shares of the biotechnology company's stock worth $128,000 after purchasing an additional 6,309 shares during the last quarter. CM Management LLC raised its position in XOMA Royalty by 16.4% in the 1st quarter. CM Management LLC now owns 64,000 shares of the biotechnology company's stock worth $1,276,000 after purchasing an additional 9,000 shares during the last quarter. Finally, GAMMA Investing LLC grew its holdings in XOMA Royalty by 1,063.8% during the 1st quarter. GAMMA Investing LLC now owns 1,734 shares of the biotechnology company's stock worth $35,000 after acquiring an additional 1,585 shares during the period. Institutional investors own 95.92% of the company's stock.

Analysts Set New Price Targets

A number of research firms have commented on XOMA. Wall Street Zen raised shares of XOMA Royalty from a "hold" rating to a "buy" rating in a report on Monday, August 11th. HC Wainwright reissued a "buy" rating and issued a $104.00 price target on shares of XOMA Royalty in a report on Wednesday, May 28th. Finally, Zacks Research raised shares of XOMA Royalty to a "hold" rating in a report on Tuesday, August 12th. Two research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $69.50.

XOMA Royalty Stock Performance

XOMA traded up $0.44 on Monday, reaching $35.68. The company had a trading volume of 18,196 shares, compared to its average volume of 44,845. XOMA Royalty Corporation has a fifty-two week low of $18.35 and a fifty-two week high of $36.32. The company's fifty day moving average is $28.83 and its 200 day moving average is $25.10. The stock has a market cap of $431.37 million, a P/E ratio of -23.02 and a beta of 0.98. The company has a debt-to-equity ratio of 1.41, a quick ratio of 4.88 and a current ratio of 4.88.

XOMA Royalty (NASDAQ:XOMA - Get Free Report) last announced its earnings results on Wednesday, August 13th. The biotechnology company reported $0.48 EPS for the quarter, topping the consensus estimate of ($0.12) by $0.60. XOMA Royalty had a negative net margin of 27.57% and a positive return on equity of 2.63%. The company had revenue of $13.13 million for the quarter, compared to analysts' expectations of $9.39 million. As a group, analysts predict that XOMA Royalty Corporation will post -1.41 earnings per share for the current fiscal year.

About XOMA Royalty

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.